Highlights
- Early disclosure of plasma p-tau217 and neurofilament light chain (NfL) biomarkers markedly increases etiologic diagnostic certainty in patients with SCD, MCI, and mild dementia.
- Earlier biomarker knowledge leads to earlier initiation of symptomatic Alzheimer’s disease (AD) treatments and streamlined clinical management including fewer follow-up neuropsychological assessments.
- Integration of blood-based biomarker results into routine diagnostic pathways does not adversely affect patients’ emotional well-being.
- The benefits are especially sustained in patients with mild cognitive impairment, highlighting a potential window for timely intervention.
Background
Alzheimer disease (AD) remains a leading cause of dementia worldwide, with an urgent need for earlier and accurate diagnosis to guide therapy and care planning. The development of blood-based biomarkers, such as plasma phosphorylated tau at threonine 217 (p-tau217) and neurofilament light chain (NfL), has revolutionized noninvasive detection of AD pathology and neurodegeneration. These biomarkers provide a cost-effective, accessible alternative to cerebrospinal fluid and PET imaging biomarkers. Despite their diagnostic accuracy, evidence regarding how early disclosure of such biomarkers influences clinicians’ diagnostic confidence, clinical decisions, and patients’ psychological impact in routine care has been limited. The randomized clinical trial by Estragués-Gázquez et al., published in 2026, addresses this critical gap by systematically assessing the effects of earlier biomarker disclosure compared to delayed information provision in a real-world memory clinic setting.
Key Content
Study Design and Participant Characteristics
The trial enrolled 265 consecutive outpatients at a single Spanish memory clinic presenting with subjective cognitive decline (SCD), mild cognitive impairment (MCI), or mild dementia without a prior etiologic diagnosis. After eligibility, 220 participants (median age 73, 56% women) were randomized to receive disclosure of plasma p-tau217 and NfL results at either 3 months (earlier-disclosure arm) or 9 months (delayed-disclosure arm). The study’s 9-month follow-up allowed comparison of diagnostic certainty, clinical management, and emotional outcomes including anxiety, depression, stress, and quality of life.
Diagnostic Certainty Enhancement with Early Biomarker Disclosure
At the 3-month visit, 50.0% of participants in the earlier-disclosure arm had attained a very high-confidence etiologic diagnosis (defined as ≥90% certainty), versus only 4.6% in the delayed arm (P < .001). After delayed disclosure at 9 months, diagnostic certainty in the delayed arm increased and mostly converged with the earlier-disclosure arm. Notably, participants with MCI retained significantly higher diagnostic certainty in the earlier-disclosure group, underscoring the added value of prompt biomarker data in this critical diagnostic window.
Impact on Clinical Management
Early knowledge of biomarker status influenced clinical care trajectories significantly. Those in the earlier-disclosure arm more frequently initiated symptomatic AD treatments (14.3% vs 4.6%; difference 9.7%; P = .01), reflecting increased clinician confidence and timely therapeutic intervention. Furthermore, earlier disclosure reduced the need for repeated neuropsychological assessments aimed at clarifying diagnosis (30.4% vs 52.8%; difference -22.4%; P < .001), and increased planned discharges from specialty memory clinic settings to primary care (31.3% vs 12.0%; difference 19.2%; P < .001), suggesting greater efficiency and resource optimization.
Emotional and Quality of Life Outcomes
Importantly, earlier disclosure did not worsen emotional outcomes. Measures of anxiety, depression, perceived stress, and quality of life remained comparable between groups throughout follow-up, alleviating concerns that earlier knowledge of neurodegenerative pathology might induce psychological harm.
Context within Existing Biomarker Literature
This trial builds on earlier studies validating p-tau217 and NfL as robust blood-based markers for AD pathology and neurodegeneration, respectively. Prior work (Palmqvist et al., Lancet Neurol 2022; Janelidze et al., Nat Med 2020) demonstrated their high diagnostic and prognostic accuracy in cross-sectional and longitudinal cohorts. However, Estragués-Gázquez et al. break new ground by evaluating pragmatic outcomes of biomarker integration into routine care pathways.
Other observational studies and guideline updates by the International Working Group (IWG) and Alzheimer’s Association have increasingly advocated blood-based biomarkers for earlier detection and stratification. Nevertheless, randomized trial evidence on clinical impact and safety had been lacking until now.
Expert Commentary
The findings provide compelling evidence that earlier disclosure of blood-based biomarkers meaningfully refines diagnostic clarity and promotes more decisive clinical management, aligning with the current paradigm shift toward precision medicine in dementia care. The significant impact observed in the MCI subgroup is particularly noteworthy, given the diagnostic uncertainty and therapeutic window at this stage.
Clinicians have historically grappled with uncertainty in dementia diagnosis, often relying heavily on clinical assessments and imaging, which may be costly or inaccessible. Blood biomarkers offer scalable, less invasive alternatives, and this trial supports their integration into diagnostic algorithms.
Moreover, the absence of negative emotional consequences challenges prior apprehensions that early biomarker disclosure could exacerbate patient distress. This underscores the importance of careful counseling and shared decision-making facilitated by biomarker information.
Limitations include the single-center design and relatively short follow-up; broader multicenter studies and longer-term outcomes are warranted. Additionally, the study focused on two biomarkers, and future research might incorporate emerging markers such as plasma Aβ42/40 ratios or GFAP.
Conclusion
Estragués-Gázquez et al.’s randomized clinical trial provides high-quality evidence that earlier disclosure of plasma p-tau217 and NfL biomarkers substantially enhances etiologic diagnostic certainty in patients with cognitive complaints and leads to timely, tailored clinical management, without increasing emotional distress. These results advocate for incorporating blood-based biomarkers into standard memory clinic diagnostic workflows to improve care efficiency and patient outcomes, particularly at the MCI stage where interventions may have maximal impact.
Future directions include validation across diverse populations, integration with multimodal biomarkers and digital tools, and evaluation of cost-effectiveness and health system impact. As blood-based biomarkers become more widely available, this trial offers a pivotal evidence base for clinicians and policymakers aiming to optimize dementia diagnosis and management in clinical practice.
References
- Estragués-Gázquez I, Contador J, Martínez LD, et al. Earlier Disclosure of Blood-Based Biomarkers, Diagnostic Certainty, and Clinical Management: A Randomized Clinical Trial. JAMA Neurol. 2026 Oct 5;PMID: 42832237.
- Palmqvist S, et al. Plasma phospho-tau217 predicts amyloid and tau pathology and clinical progression in Alzheimer’s disease. Lancet Neurol. 2022;21(7):484-496.
- Janelidze S, et al. Plasma P-tau217 and P-tau181 as biomarkers of Alzheimer’s disease pathology. Nat Med. 2020;26(2):293-298.
- Mattsson N, et al. Clinical validity of plasma neurofilament light: a meta-analysis. Neurology. 2019;93(21):e2109-e2118.
- Jack CR Jr, Bennett DA, et al. NIA-AA Research Framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018;14(4):535-562.
